| __timestamp | Catalent, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1229100000 | 21226345 |
| Thursday, January 1, 2015 | 1215500000 | 139626 |
| Friday, January 1, 2016 | 1260500000 | 93831530 |
| Sunday, January 1, 2017 | 1420800000 | 79419009 |
| Monday, January 1, 2018 | 1710800000 | 368673 |
| Tuesday, January 1, 2019 | 1712900000 | 477121 |
| Wednesday, January 1, 2020 | 2111000000 | 1895029 |
| Friday, January 1, 2021 | 2646000000 | 8034589 |
| Saturday, January 1, 2022 | 3188000000 | 20443000 |
| Sunday, January 1, 2023 | 3216000000 | 33745000 |
| Monday, January 1, 2024 | 3428000000 |
Igniting the spark of knowledge
In the dynamic world of pharmaceuticals, understanding cost structures is crucial. This chart compares the cost of revenue for Intra-Cellular Therapies, Inc. and Catalent, Inc. from 2014 to 2023. Catalent, Inc., a leader in drug development solutions, consistently shows a robust cost of revenue, peaking at approximately $3.4 billion in 2024, reflecting a 179% increase from 2014. In contrast, Intra-Cellular Therapies, Inc., a company focused on innovative treatments for neuropsychiatric disorders, exhibits a more volatile pattern. Their cost of revenue surged by over 1,500% from 2015 to 2023, highlighting their aggressive growth and investment in research. However, data for 2024 is missing, indicating potential reporting delays or strategic shifts. This comparison underscores the diverse financial strategies within the pharmaceutical industry, where scale and innovation drive distinct cost trajectories.
Cost Insights: Breaking Down AbbVie Inc. and Intra-Cellular Therapies, Inc.'s Expenses
Cost Insights: Breaking Down Merck & Co., Inc. and Catalent, Inc.'s Expenses
Analyzing Cost of Revenue: Pfizer Inc. and Catalent, Inc.
Amgen Inc. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Biogen Inc. and Intra-Cellular Therapies, Inc.'s Expenses
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Grifols, S.A.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Cytokinetics, Incorporated
Intra-Cellular Therapies, Inc. vs Alkermes plc: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Catalent, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored